HMG CoA Reductase and lnsig-1: Regulatory Roles of ERAD

$429,733P01FY2012HLNIH

Ut Southwestern Medical Center, Dallas TX

Investigators

Linked publications & trials

Paper 39223695 Paper 38602170 Paper 37168434 Paper 36891609 Paper 36758549 Paper 35940903 Paper 35914126 Paper 35879350 Paper 35857506 Paper 35831507 Paper 35785158 Paper 35672408 Paper 35556261 Paper 35537452 Paper 35533983 Paper 35467977 Paper 35461764 Paper 35379782 Paper 35353559 Paper 34992143 Paper 34923175 Paper 34842525 Paper 34793833 Paper 34782454 Paper 34754073 Paper 34698632 Paper 34562244 Paper 34521750 Paper 34520735 Paper 34499619 Paper 34407950 Paper 34404721 Paper 34139175 Paper 33748712 Paper 33741963 Paper 33712199 Paper 33658436 Paper 33619548 Paper 33476560 Paper 33408073 Paper 33310904 Paper 33199907 Paper 33110211 Paper 33106423 Paper 33103159 Paper 33070362 Paper 32929279 Paper 32913007 Paper 32859645 Paper 32808593 Paper 32792680 Paper 32764564 Paper 32730227 Paper 32690708 Paper 32661016 Paper 32646941 Paper 32646883 Paper 32487748 Paper 32433613 Paper 32327483 Paper 32311334 Paper 32284563 Paper 32259482 Paper 32208993 Paper 32188638 Paper 32163279 Paper 32118581 Paper 32095534 Paper 32052833 Paper 31919352 Paper 31657721 Paper 31653658 Paper 31597703 Paper 31588013 Paper 31587991 Paper 31513923 Paper 31310592 Paper 31168089 Paper 31165728 Paper 31019090 Paper 30923116 Paper 30910968 Paper 30835201 Paper 30808712 Paper 30802989 Paper 30790255 Paper 30785396 Paper 30712872 Paper 30700132 Paper 30610175 Paper 30610084 Paper 30530852 Paper 30403941 Paper 30305615 Paper 30272579 Paper 30139912 Paper 30138538 Paper 30103710 Paper 30047864 Paper 30046014

Abstract

HMG CoA reductase is the molecular target of statins, a group of drugs that are widely prescribed to lower plasma LDL-cholesterol and to reduce the incidence of cardiovascular disease in humans. Statins trigger regulatory responses that result in the marked accumulation of reductase that blunts the clinical effects of the drugs. Part of this increase is likely due to slowed ERAD of reductase. Thus, understanding the mechanisms of reductase ERAD may lead to the development of new drugs to counteract the accumulation of reductase that accompanies statin treatment. In some cases these drugs may provide alternatives to statin therapy.

View original record on NIH RePORTER →